Alan So

8.3k citations
200 papers · 5.3k indexed · h-index 43

Alan So

192 papers receiving 5.2k citations

Peers

Alan So
Comparison fields: 5 of 141
  • Pulmonary and Respiratory Medicine 2.0k
  • Urology 381
  • Cancer Research 866
  • Oncology 1.4k
  • Molecular Biology 2.2k
Replace Robert H. Getzenberg with:
Robert H. Getzenberg United States
Yasutomo Nasu Japan
Hing Y. Leung United Kingdom
Egbert Oosterwijk Netherlands
Robert J. Amato United States
Ganesh S. Palapattu United States
Srikala S. Sridhar Canada
Srinivasan Yegnasubramanian United States
Daniel Fink Switzerland
Louis Denis United States
Alan So relative to Robert H. Getzenberg United States Robert H. Getzenberg's profile →
Citations per field
00.5×1.5×2.2×
Robert H. Getzenberg · 1×
Citations per year

Countries citing papers authored by Alan So

Since Specialization
Citations

This map shows the geographic impact of Alan So's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan So with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan So more than expected).

Fields of papers citing papers by Alan So

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan So. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan So. The network helps show where Alan So may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Alan So, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Alan So Line = papers co-authored together Alan So links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20250
2 20241
3 202113
4 20219
5 20207
6 20192
7 201923
8 20194
9 20185
10 201762
11 201727
12 201524
13 201531
14 201518
15 201543
16 20134
17 20126
18 201151
19 200856
20 2004185

About Alan So

Alan So is a scholar working on Urology, Pulmonary and Respiratory Medicine and Oncology, having authored 200 papers that have together received 5.3k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (56 papers), Bladder and Urothelial Cancer Treatments (54 papers), Prostate Cancer Diagnosis and Treatment (47 papers), Renal cell carcinoma treatment (34 papers), Urinary and Genital Oncology Studies (25 papers), Renal and related cancers (24 papers), Urological Disorders and Treatments (16 papers) and Cancer, Lipids, and Metabolism (14 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (2.0k citations), Urology (381 citations) and Cancer Research (866 citations). Alan So has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include Martin Gleave, Ladan Fazli, Palma Rocchi, Peter C. Black, Antonio Hurtado‐Coll, Eliana Beraldi, Boris Hadaschik, Ricardo Rendon, Fred Saad and Colleen C. Nelson. Their work appears in journals such as Journal of Clinical Oncology, British Journal of Urology, Urologic Oncology Seminars and Original Investigations, The Journal of Urology and World Journal of Urology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026